Anti-Evolocumab Antibodies
-
Bioanalytical Antibodies
-
Anti-idiotypic Antibodies
- Antibodies for Bioanalysis and Drug Monitoring
- Anti-Abatacept Antibodies
- Anti-Adalimumab Antibodies
- Anti-Alemtuzumab Antibodies
- Anti-Bevacizumab Antibodies
- Anti-Brentuximab Antibodies
- Anti-Cemiplimab Antibodies
- Anti-Certolizumab Antibodies
- Anti-Cetuximab Antibodies
- Anti-Daratumumab Antibodies
- Anti-Denosumab Antibodies
- Anti-Dupilumab Antibodies
- Anti-Durvalumab Antibodies
- Anti-Eculizumab Antibodies
- Anti-Etanercept Antibodies
- Anti-Evolocumab Antibodies
- Anti-Golimumab Antibodies
- Anti-Infliximab Antibodies
- Anti-Ipilimumab Antibodies
- Anti-Natalizumab Antibodies
- Anti-Nivolumab Antibodies
- Anti-Omalizumab Antibodies
- Anti-Palivizumab Antibodies
- Anti-Panitumumab Antibodies
- Anti-Pembrolizumab Antibodies
- Anti-Pertuzumab Antibodies
- Anti-Ranibizumab Antibodies
- Anti-Rituximab Antibodies
- Anti-Secukinumab Antibodies
- Anti-Tocilizumab Antibodies
- Anti-Trastuzumab Antibodies
- Anti-Ustekinumab Antibodies
- Anti-Vedolizumab Antibodies
- Biosimilar Antibodies for Research Use
- Anti-IgG Fc Antibodies
- Recombinant Fully-Human Immunoglobulin Isotype Controls
- Anti-Biotherapeutic Antibody Quality Control and Characterization
- Characterization of Critical Reagents for Ligand Binding Assays
-
Anti-idiotypic Antibodies
s
s
s
Antibodies for bioanalysis and drug monitoring of evolocumab and biosimilars
Develop highly selective and sensitive pharmacokinetic (PK) and anti-drug antibody (ADA) assays for the monoclonal antibody evolocumab (Repatha) using our range of ready-made antibodies.
- Recombinant antibodies specific to evolocumab
- TrailBlazer Antibodies enabling site-directed conjugation and format switching
- Fully human format for surrogate positive control or calibrator
- Sequence-defined, well characterized reagents with secure supply
- Stringent quality control for batch-to-batch consistency
Table 1. Antibodies Specific to Evolocumab.
Specificity |
Catalog Number |
Clone |
Format |
Affinity* KD, nM |
Assay Recommendation |
Product Details |
|---|---|---|---|---|---|---|
|
Evolocumab Inhibitory Type 1 |
TZA007 |
AbD40406ad |
Fab-F-Spy2-H1 |
1 |
PK bridging ELISA |
|
|
TZA008 |
AbD40410ad |
Fab-F-Spy2-H1 |
5 |
PK bridging ELISA |
||
|
HCA376 |
AbD40410ia |
Human IgG1 |
5 |
PK bridging ELISA ADA control |
||
|
HCA377 |
AbD40406ia |
Human IgG1 |
1 |
ADA control |
||
|
HCA378 |
AbD40405ia |
Human IgG1 |
5 |
ADA control |
* Affinity measured in the monovalent Fab format.
1 Monovalent Fab antibody with (F) DYKDDDDK, (Spy2) SpyTag version 2, and (H) His-6-tags.
Anti-Evolocumab Inhibitory Antibodies (Type 1)
Type 1 anti-evolocumab antibodies inhibit the binding of the monoclonal antibody drug evolocumab to its target, human proprotein convertase subtilisin/kexin type 9 (PCSK9). They are ideal for development of a PK bridging ELISA to measure free drug. Three clones are available in fully human IgG1 format for use as a surrogate positive control or reference standard in an ADA assay.
TrailBlazer Antibodies, clones AbD40406ad (TZA007) and AbD40410ad (TZA008), have a SpyTag2 incorporated at the C-terminus of the antibody heavy chain. In a fast reaction, that simply requires mixing at room temperature, these antibodies can form a covalent isopeptide bond to a SpyCatcher reagent, enabling site-directed conjugation or fast conversion to a bivalent Fab or a full-length Ig-like format within an hour.
ELISA Protocols to Get You Started
PK Bridging ELISA
Fig. 1. Evolocumab PK bridging ELISA using antibodies TZA007 and HCA376.
Schematic image of PK bridging ELISA measuring free drug. Anti-idiotypic capture antibody, Fab format (purple), monoclonal antibody drug (gold), anti-idiotypic detection antibody, Ig format (blue), labeled with HRP.
ADA Bridging ELISA
Fig. 2. Evolocumab ADA bridging ELISA using antibody HCA376, HCA377, or HCA378.
Schematic image of ADA bridging assay. Monoclonal antibody drug as capture antibody and detection antibody labeled with HRP (gold), fully human anti-idiotypic antibody, Ig format (blue).
Related Products
Resources
Licensed Use: For in vitro research purposes and for commercial applications for the provision of in vitro testing services to support preclinical and clinical drug development. Any re-sale in any form or any other commercial application needs a written agreement with Bio-Rad.